Increase 68Ga-FAPI Uptake in Urogenital Tuberculosis.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Urogenital tuberculosis is one of common sites of extrapulmonary tuberculosis. A 60-year-old man with an elevated prostate-specific antigen level underwent multiparametric MRI, which revealed abnormal signals in the prostate. However, the 68Ga-PSMA PET/CT results were unrevealing. Subsequent 68Ga-FAPI PET/CT imaging revealed intense radioactivity uptake in the prostate and mild radioactivity uptake in the left kidney, which was eventually proven due to tuberculosis.
Identifiants
pubmed: 39193937
doi: 10.1097/RLU.0000000000005418
pii: 00003072-990000000-01261
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Muneer A, Macrae B, Krishnamoorthy S, et al. Urogenital tuberculosis—epidemiology, pathogenesis and clinical features. Nat Rev Urol. 2019;16:573–598.
Kamra E, Mehta PK. Current updates in diagnosis of male urogenital tuberculosis. Expert Rev Anti Infect Ther. 2021;19:1175–1190.
Naeem M, Zulfiqar M, Siddiqui MA, et al. Imaging manifestations of genitourinary tuberculosis. Radiographics. 2021;41:1123–1143.
Kulchavenya E, Kholtobin D, Shevchenko S. Challenges in urogenital tuberculosis. World J Urol. 2020;38:89–94.
Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405–412.
Chandekar KR, Singh H, Kumar R, et al. Comparison of 18F-PSMA-1007 PET/CT with 68Ga-PSMA-11 PET/CT for initial staging in intermediate- and high-risk prostate cancer. Clin Nucl Med. 2023;48:e1–e8.
Skyum SM, Anthonsen AK, Salkus G, et al. Intravenous pyogenic granuloma in the inguinal canal mimicking lymph node metastasis on PSMA PET/CT. Clin Nucl Med. 2023;48:e500–e502.
Wu S, Pang Y, Zhao L, et al. 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for the evaluation of disease activity in takayasu arteritis. Clin Nucl Med. 2021;46:847–849.
Mori Y, Dendl K, Cardinale J, et al. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306:e220749.
Zhou W, Sun J, Wang F, et al. Displays of 18F-FAPI PET/CT in myocarditis with variable symptom durations. Clin Nucl Med. 2023;48:799–801.
Pang Y, Zhao L, Meng T, et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study. J Nucl Med. 2023;64:386–394.
Liu W, Gong W, Yang X, et al. Increased FAPI activity in pulmonary tuberculosis. Clin Nucl Med. 2023;48:188–189.
Alcin G, Tatar G, Sahin R, et al. Peritoneal tuberculosis mimicking peritoneal carcinomatosis on 68Ga-FAPI-04 and 18F-FDG PET/CT. Clin Nucl Med. 2022;47:e557–e558.
Gu B, Luo Z, He X, et al. 68Ga-FAPI and 18F-FDG PET/CT images in a patient with extrapulmonary tuberculosis mimicking malignant tumor. Clin Nucl Med. 2020;45:865–867.
Gong W, Yang X, Mou C, et al. Bone tuberculous granulomatous inflammation mimicking malignancy on 68Ga-FAPI PET/CT. Clin Nucl Med. 2022;47:348–349.
Sun R, Huang Z, Wei J, et al. 68Ga-FAPI and 18F-FDG PET/CT findings in a patient with pancreatic tuberculosis mimicking malignant tumor. Clin Nucl Med. 2022;47:653–654.